PMC:7426526 / 30913-31393 JSONTXT

{"project":"TEST0","denotations":[{"id":"32849491-68-74-3396372","span":{"begin":73,"end":75},"obj":"[\"28270302\"]"},{"id":"32849491-99-106-3396373","span":{"begin":177,"end":180},"obj":"[\"21116281\"]"},{"id":"32849491-104-111-3396374","span":{"begin":182,"end":185},"obj":"[\"24375249\"]"},{"id":"32849491-93-100-3396375","span":{"begin":281,"end":284},"obj":"[\"26170984\"]"},{"id":"32849491-96-103-3396376","span":{"begin":383,"end":386},"obj":"[\"26170984\"]"},{"id":"32849491-86-93-3396377","span":{"begin":475,"end":478},"obj":"[\"27458532\"]"}],"text":"CD44\nAs mentioned above, CD44 is a common marker shared by many cancers (60). In hematological cancers, CD44 expression is functionally associated with chemotherapy resistance (488, 489). The expression of CD44 in AML is significantly correlated with a poor overall survival (OS) (490). Furthermore, CD44 was shown to be significantly higher expressed in non-remission AML patients (490). A highly relevant function of CD44 for LSCs is the adhesion to the bone marrow niche (491)."}

{"project":"MyTest","denotations":[{"id":"32849491-28270302-34970752","span":{"begin":73,"end":75},"obj":"28270302"},{"id":"32849491-21116281-34970753","span":{"begin":177,"end":180},"obj":"21116281"},{"id":"32849491-24375249-34970754","span":{"begin":182,"end":185},"obj":"24375249"},{"id":"32849491-26170984-34970755","span":{"begin":281,"end":284},"obj":"26170984"},{"id":"32849491-26170984-34970756","span":{"begin":383,"end":386},"obj":"26170984"},{"id":"32849491-27458532-34970757","span":{"begin":475,"end":478},"obj":"27458532"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"CD44\nAs mentioned above, CD44 is a common marker shared by many cancers (60). In hematological cancers, CD44 expression is functionally associated with chemotherapy resistance (488, 489). The expression of CD44 in AML is significantly correlated with a poor overall survival (OS) (490). Furthermore, CD44 was shown to be significantly higher expressed in non-remission AML patients (490). A highly relevant function of CD44 for LSCs is the adhesion to the bone marrow niche (491)."}

{"project":"2_test","denotations":[{"id":"32849491-28270302-34970752","span":{"begin":73,"end":75},"obj":"28270302"},{"id":"32849491-21116281-34970753","span":{"begin":177,"end":180},"obj":"21116281"},{"id":"32849491-24375249-34970754","span":{"begin":182,"end":185},"obj":"24375249"},{"id":"32849491-26170984-34970755","span":{"begin":281,"end":284},"obj":"26170984"},{"id":"32849491-26170984-34970756","span":{"begin":383,"end":386},"obj":"26170984"},{"id":"32849491-27458532-34970757","span":{"begin":475,"end":478},"obj":"27458532"}],"text":"CD44\nAs mentioned above, CD44 is a common marker shared by many cancers (60). In hematological cancers, CD44 expression is functionally associated with chemotherapy resistance (488, 489). The expression of CD44 in AML is significantly correlated with a poor overall survival (OS) (490). Furthermore, CD44 was shown to be significantly higher expressed in non-remission AML patients (490). A highly relevant function of CD44 for LSCs is the adhesion to the bone marrow niche (491)."}